Bezirkskliniken Schwaben KU Anstalt des offentlichen Rechts des Bezirks Schwaben
- Address
- Geschwister-Schoenert-Strasse 1, Kriegshaber, 86156 Augsburg, Germany
Bezirkskliniken Schwaben - Psychiatric Research Center
Bezirkskliniken Schwaben is a leading psychiatric research institution specializing in innovative treatment approaches for severe mental health disorders. The center focuses on advancing pharmacological interventions and exploring novel therapeutic mechanisms, particularly in conditions that are challenging to treat with conventional approaches.
- Schizophrenia spectrum disorders, including first-episode treatment failures and cognitive dysfunction
- Treatment-resistant depression with augmentation strategies
- Myelin plasticity and neurobiological mechanisms in psychiatric disorders
The center's research portfolio demonstrates a commitment to addressing treatment-resistant conditions through both early-intensified pharmacological interventions and innovative combination therapies. Notable research includes investigating myelin plasticity as a target for cognitive improvement in schizophrenia, combining pharmacological agents like clemastine with aerobic exercise, and exploring hormonal augmentation strategies such as DHEA supplementation for depression. The institution emphasizes rigorous randomized controlled trial methodologies to evaluate functional outcomes, symptom severity reduction, and cognitive performance improvements in patients with schizophrenia, schizoaffective disorders, and treatment-resistant depression.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 therapeutic areas and 15 of 28 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Apurano Pharmaceuticals GmbH1active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Bezirkskliniken Schwaben KU Anstalt des offentlichen Rechts des Bezirks Schwaben
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of AP707 in Patients with Borderline Personality Disorder: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial | Apurano Pharmaceuticals GmbH | Phase II | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 28 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Adezunap | 1 | Unknown | — | — |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.